These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 31225609)

  • 21. Rilpivirine, emtricitabine and tenofovir resistance in HIV-1-infected rilpivirine-naive patients failing antiretroviral therapy.
    Lambert-Niclot S; Charpentier C; Storto A; Fofana D; Soulie C; Fourati S; Wirden M; Morand-Joubert L; Masquelier B; Flandre P; Calvez V; Descamps D; Marcelin AG
    J Antimicrob Chemother; 2014 Apr; 69(4):1086-9. PubMed ID: 24302653
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.
    Cohen CJ; Andrade-Villanueva J; Clotet B; Fourie J; Johnson MA; Ruxrungtham K; Wu H; Zorrilla C; Crauwels H; Rimsky LT; Vanveggel S; Boven K;
    Lancet; 2011 Jul; 378(9787):229-37. PubMed ID: 21763935
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment.
    McGowan I; Dezzutti CS; Siegel A; Engstrom J; Nikiforov A; Duffill K; Shetler C; Richardson-Harman N; Abebe K; Back D; Else L; Egan D; Khoo S; Egan JE; Stall R; Williams PE; Rehman KK; Adler A; Brand RM; Chen B; Achilles S; Cranston RD
    Lancet HIV; 2016 Dec; 3(12):e569-e578. PubMed ID: 27658864
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Penetration and antiviral efficacy of total and unbound maraviroc, raltegravir and rilpivirine in both female and male genital fluids from HIV-positive patients receiving regimens containing these antiretrovirals.
    Lê MP; Belarbi L; Chaix ML; Dulioust E; Mahjoub N; Salmon D; Viard JP; Duvivier C; Peytavin G; Launay O; Ghosn J
    J Antimicrob Chemother; 2017 Nov; 72(11):3167-3171. PubMed ID: 28961979
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lipid levels and changes in body fat distribution in treatment-naive, HIV-1-Infected adults treated with rilpivirine or Efavirenz for 96 weeks in the ECHO and THRIVE trials.
    Tebas P; Sension M; Arribas J; Duiculescu D; Florence E; Hung CC; Wilkin T; Vanveggel S; Stevens M; Deckx H;
    Clin Infect Dis; 2014 Aug; 59(3):425-34. PubMed ID: 24729492
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-world persistence with antiretroviral therapy for HIV in the United Kingdom: A multicentre retrospective cohort study.
    Lewis JM; Smith C; Torkington A; Davies C; Ahmad S; Tomkins A; Shaw J; Kingston M; Muqbill G; Hay P; Mulka L; Williams D; Waters L; Brima N; Marshall N; Johnson M; Chaponda M; Nelson M
    J Infect; 2017 Apr; 74(4):401-407. PubMed ID: 28143756
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Viral blips were infrequent in treatment-naive adults treated with rilpivirine/emtricitabine/tenofovir DF or efavirenz/emtricitabine/tenofovir DF through 96 weeks.
    Porter DP; Kulkarni R; Garner W; Miller MD; White KL
    Antivir Ther; 2017; 22(6):495-502. PubMed ID: 28091393
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatment.
    Wilkins EL; Cohen CJ; Trottier B; Esser S; Smith DE; Haas B; Brinson C; Garner W; Chuck S; Thorpe D; De-Oertel S
    AIDS Care; 2016; 28(3):401-8. PubMed ID: 26489045
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasma and Intracellular Concentrations in HIV-Infected Patients Requiring Hemodialysis Dosed With Tenofovir Disoproxil Fumarate and Emtricitabine.
    Slaven JE; Decker BS; Kashuba ADM; Atta MG; Wyatt CM; Gupta SK
    J Acquir Immune Defic Syndr; 2016 Sep; 73(1):e8-e10. PubMed ID: 27285451
    [No Abstract]   [Full Text] [Related]  

  • 30. Lowered Rilpivirine Exposure During the Third Trimester of Pregnancy in Human Immunodeficiency Virus Type 1-Infected Women.
    Schalkwijk S; Colbers A; Konopnicki D; Gingelmaier A; Lambert J; van der Ende M; Moltó J; Burger D;
    Clin Infect Dis; 2017 Oct; 65(8):1335-1341. PubMed ID: 28595298
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Switch from unboosted protease inhibitor to a single-tablet regimen containing rilpivirine improves cholesterol and triglycerides.
    Di Biagio A; Riccardi N; Taramasso L; Capetti A; Cenderello G; Signori A; Vitiello P; Guerra M; de Socio GV; Cassola G; Quirino T; Viscoli C
    Int J Antimicrob Agents; 2016 Nov; 48(5):551-554. PubMed ID: 27566908
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of rilpivirine and 24-week outcomes after switching from efavirenz in virologically suppressed HIV-1-infected adolescents.
    Jantarabenjakul W; Anugulruengkitt S; Kasipong N; Thammajaruk N; Sophonphan J; Bunupuradah T; Cressey TR; Colbers A; Burger DM; Phongsamart W; Puthanakit T; Pancharoen C;
    Antivir Ther; 2018; 23(3):259-265. PubMed ID: 28994660
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dolutegravir plasma concentrations according to companion antiretroviral drug: unwanted drug interaction or desirable boosting effect?
    Cattaneo D; Minisci D; Cozzi V; Riva A; Meraviglia P; Clementi E; Galli M; Gervasoni C
    Antivir Ther; 2017; 22(4):353-356. PubMed ID: 28008867
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of dolutegravir and rilpivirine in combination with simeprevir and sofosbuvir in HIV/hepatitis C virus-coinfected patients with liver cirrhosis.
    Merli M; Galli L; Marinaro L; Ariaudo A; Messina E; Uberti-Foppa C; Castagna A; D'Avolio A; Lazzarin A; Bonora S; Hasson H
    J Antimicrob Chemother; 2017 Mar; 72(3):812-815. PubMed ID: 27999010
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies.
    Llibre JM; Hung CC; Brinson C; Castelli F; Girard PM; Kahl LP; Blair EA; Angelis K; Wynne B; Vandermeulen K; Underwood M; Smith K; Gartland M; Aboud M
    Lancet; 2018 Mar; 391(10123):839-849. PubMed ID: 29310899
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety in clinical practice of a rilpivirine, tenofovir and emtricitabine single-tablet regimen in virologically suppressed HIV-positive patients on stable antiretroviral therapy.
    Gianotti N; Poli A; Nozza S; Spagnuolo V; Tambussi G; Bossolasco S; Cinque P; Maillard M; Cernuschi M; Galli L; Lazzarin A; Castagna A
    J Int AIDS Soc; 2015; 18(1):20037. PubMed ID: 26232000
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens.
    Mills AM; Cohen C; Dejesus E; Brinson C; Williams S; Yale KL; Ramanathan S; Wang MH; White K; Chuck SK; Cheng AK
    HIV Clin Trials; 2013; 14(5):216-23. PubMed ID: 24144898
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of the mutational load on the virological response to a first-line rilpivirine-based regimen.
    Dimeglio C; Raymond S; Nicot F; Jeanne N; Carcenac R; Lefebvre C; Izopet J;
    J Antimicrob Chemother; 2019 Mar; 74(3):718-721. PubMed ID: 30535228
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Factors associated with pre-treatment HIV RNA: application for the use of abacavir and rilpivirine as the first-line regimen for HIV-infected patients in resource-limited settings.
    Kiertiburanakul S; Boettiger D; Ng OT; Van Kinh N; Merati TP; Avihingsanon A; Wong WW; Lee MP; Chaiwarith R; Kamarulzaman A; Kantipong P; Zhang F; Choi JY; Kumarasamy N; Ditangco R; Cuong DD; Oka S; Sim BLH; Ratanasuwan W; Ly PS; Yunihastuti E; Pujari S; Ross JL; Law M; Sungkanuparph S;
    AIDS Res Ther; 2017; 14():27. PubMed ID: 28484509
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of rilpivirine in clinical practice: strengths and weaknesses of the new nonnucleoside reverse transcriptase inhibitor for HIV therapy.
    Imaz A; Podzamczer D
    AIDS Rev; 2012; 14(4):268-78. PubMed ID: 23258301
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.